logo
Select company
Select metric
$ -94.15MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
8
Sector
20
Industry
30
History
68
$ 57.77Close
$ 7.36 - $ 60.55 52-Week Range
Ticker Information

Ticker

NKTR

Company Name

NEKTAR THERAPEUTICS

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

NEKTAR THERAPEUTICS - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

NKTR - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 1.97M$ -96.12M$ -94.15M
3/31/2025$ 3.21M$ -105.64M$ -102.43M
12/31/2024$ 4.39M$ -91.09M$ -86.7M
9/30/2024$ 5.71M$ -143.48M$ -137.77M
6/30/2024$ 6.41M$ -152.44M$ -146.03M
3/31/2024$ 7.12M$ -151.55M$ -144.43M
12/31/2023$ 7.82M$ -250.92M$ -243.11M
9/30/2023$ 9.35M$ -265.02M$ -255.68M
6/30/2023$ 10.33M$ -277.29M$ -266.96M
3/31/2023$ 11.6M$ -384.01M$ -372.41M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • NEKTAR THERAPEUTICS's latest trailing twelve months (TTM) EBITDA stands at $ -382.69M.
  • Over the past 5 years, NEKTAR THERAPEUTICS's average EBITDA has been $ -297.93M.
  • The median EBITDA for NEKTAR THERAPEUTICS during this period was $ -347.73M
  • NEKTAR THERAPEUTICS reached its highest EBITDA over the past 5 years at $ -86.7M.
  • The lowest EBITDA recorded by NEKTAR THERAPEUTICS in the same timeframe $ -474.57M

NEKTAR THERAPEUTICS's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
YMAB : Y-MABS THERAPEUTICS INC $ -26.3MLXRX : LEXICON PHARMACEUTICALS INC $ -107.44MADCT : ADC THERAPEUTICS SA $ -115.26MKURA : KURA ONCOLOGY INC $ -192.46MSAGE : SAGE THERAPEUTICS INC $ -300.6MTBPH : THERAVANCE BIOPHARMA INC $ 48.42MTRDA : ENTRADA THERAPEUTICS INC $ -73MXOMA : XOMA ROYALTY CORP $ -2.98MGOSS : GOSSAMER BIO INC $ -128.59MCDXS : CODEXIS INC $ -46.09M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for NEKTAR THERAPEUTICS is calculated as follows: EBIT [ $ -397.2M ] + DepAmor [ $ 14.51M ]
(=) EBITDA [ $ -382.69M ]

NKTR - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -474.57M

Minimum

Jun 30, 2022

$ -86.7M

Maximum

Dec 31, 2024

$ -297.93M

Average

$ -347.73M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M